Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Research Report 2026(Status and Outlook)
Radionuclide drug conjugates (RDCs) are a new type of diagnostic and therapeutic drug that combines the advantages of precise targeting and powerful killing. Nuclear medicine/radiopharmaceuticals refer to radioactive isotope preparations or a special type of medical drugs labeled with radioactive isotopes. Unlike tumor radiotherapy, nuclear medicine can radiate from the inside out at the site that needs to be treated, while radiotherapy is radiation delivered from the outside in. When the same radiation dose is given, nuclear medicine can target the target site more directly. RDC combines radionuclides with ligands (such as antibodies, peptides, small molecules, etc.) through linkers and chelators. After the targeted carrier recognizes the tumor cells, it transports the carried nuclides to the location of the target cells, achieving early and specific diagnosis of the disease at the molecular level, or giving tumor tissues in cancer treatment a radiation dose higher than that of healthy tissues. Therefore, it plays an important role in the diagnosis of cardiovascular diseases, neurodegenerative diseases, and the treatment and efficacy evaluation of malignant tumors. Compared with ADC, RDC has the following significant advantages: (1) RDC has more ligand forms than ADC, which can be antibodies, peptides and small molecules, and can be selected according to the characteristic targets of different tumor cells. Peptides or small molecules as ligands are much smaller in size than ADC, making it easier to enter the internal tissue of the tumor and play a killing role; at the same time, RDC is highly concentrated within a range of several times the diameter of the cancer cell, thereby minimizing damage to the surrounding normal tissue. (2) ADC needs to enter the cell through endocytosis and release the biologically active payload after lysosomal degradation, thereby inducing tumor cell apoptosis. In contrast, RDC does not need to enter the tumor cell or break the linker to release the payload; instead, it uses the radiation generated by the radionuclide of RDC during decay to kill the target cell, thereby improving the stability and safety of RDC drugs in the body. (3) RDC has better resistance to drug resistance. As long as the target cell is within the radiation radius, even if there is no corresponding antigen, RDC can play an indirect therapeutic role by directly damaging or killing the tumor cell, or cutting off the nutrient channel provided by the matrix cell to the tumor cell. (4) RDC simplifies the early diagnosis, treatment and postoperative evaluation process of cancer. The same ligand can be connected to radionuclides used for disease diagnosis and treatment, respectively, facilitating the integration of diagnosis and treatment of RDC drugs. The development and evolution of the entire nuclear medicine market has three stages: diagnostic nuclear medicines dominate, therapeutic nuclear medicines are beginning to take shape, and targeted therapeutic nuclear medicines are developing rapidly. Diagnostic RDCs (Radionuclide Drug Conjugates) are a type of innovative drug that delivers radionuclides precisely to the lesion site through targeted ligands (such as antibodies, peptides, and small molecules) to achieve early diagnosis and precise staging of the disease.
The global Diagnostic Radionuclide Drug Conjugates (RDCs) market size was estimated at USD 4722.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 11.50% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Diagnostic Radionuclide Drug Conjugates (RDCs) market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Diagnostic Radionuclide Drug Conjugates (RDCs) market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Diagnostic Radionuclide Drug Conjugates (RDCs) market.
Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Novartis
Bayer
AstraZeneca
Eli Lilly
BMS
Johnson & Johnson
Bivision
Grand Pharmaceutical Group Limited
China Isotope & Radiation Corporation
Yantai Dongcheng Pharmaceutical Group Co., Ltd.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
SmartNuclide
Full-Life Technologies
Qingdao Baheal Medical INC.
Yunnan Baiyao
TOT Biopharm International Company Limited
Nuoyu Pharmaceutical
Foshan Ruidio Medical System Co., Ltd.
Chengdu Yunke Pharmaceutical Co., Ltd.
Shandong Andike Pharmaceutical Co., Ltd.
Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.
Sinotau
Market Segmentation (by Type)
Antibody-conjugated Nuclear Medicines (ARC)
Peptide-conjugated Nuclear Medicines (PRC)
Small Molecule Conjugated Nuclear Medicines (SMRC)
Market Segmentation (by Application)
Cardiovascular
Glioma
Neuroendocrine Tumors
Breast Cancer
Pancreatic Cancer
Lung Cancer
Prostate Cancer
Liver Cancer
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Diagnostic Radionuclide Drug Conjugates (RDCs) Market
Overview of the regional outlook of the Diagnostic Radionuclide Drug Conjugates (RDCs) Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Diagnostic Radionuclide Drug Conjugates (RDCs) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Diagnostic Radionuclide Drug Conjugates (RDCs), their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Diagnostic Radionuclide Drug Conjugates (RDCs) market size was estimated at USD 4722.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 11.50% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Diagnostic Radionuclide Drug Conjugates (RDCs) market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Diagnostic Radionuclide Drug Conjugates (RDCs) market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Diagnostic Radionuclide Drug Conjugates (RDCs) market.
Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Novartis
Bayer
AstraZeneca
Eli Lilly
BMS
Johnson & Johnson
Bivision
Grand Pharmaceutical Group Limited
China Isotope & Radiation Corporation
Yantai Dongcheng Pharmaceutical Group Co., Ltd.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
SmartNuclide
Full-Life Technologies
Qingdao Baheal Medical INC.
Yunnan Baiyao
TOT Biopharm International Company Limited
Nuoyu Pharmaceutical
Foshan Ruidio Medical System Co., Ltd.
Chengdu Yunke Pharmaceutical Co., Ltd.
Shandong Andike Pharmaceutical Co., Ltd.
Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.
Sinotau
Market Segmentation (by Type)
Antibody-conjugated Nuclear Medicines (ARC)
Peptide-conjugated Nuclear Medicines (PRC)
Small Molecule Conjugated Nuclear Medicines (SMRC)
Market Segmentation (by Application)
Cardiovascular
Glioma
Neuroendocrine Tumors
Breast Cancer
Pancreatic Cancer
Lung Cancer
Prostate Cancer
Liver Cancer
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Diagnostic Radionuclide Drug Conjugates (RDCs) Market
Overview of the regional outlook of the Diagnostic Radionuclide Drug Conjugates (RDCs) Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Diagnostic Radionuclide Drug Conjugates (RDCs) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Diagnostic Radionuclide Drug Conjugates (RDCs), their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Diagnostic Radionuclide Drug Conjugates (RDCs)
1.2 Key Market Segments
1.2.1 Diagnostic Radionuclide Drug Conjugates (RDCs) Segment by Type
1.2.2 Diagnostic Radionuclide Drug Conjugates (RDCs) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 DIAGNOSTIC RADIONUCLIDE DRUG CONJUGATES (RDCS) MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 DIAGNOSTIC RADIONUCLIDE DRUG CONJUGATES (RDCS) MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Product Life Cycle
3.3 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Manufacturers (2020-2025)
3.4 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Revenue Market Share by Manufacturers (2020-2025)
3.5 Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Diagnostic Radionuclide Drug Conjugates (RDCs) Market Competitive Situation and Trends
3.8.1 Diagnostic Radionuclide Drug Conjugates (RDCs) Market Concentration Rate
3.8.2 Global 5 and 10 Largest Diagnostic Radionuclide Drug Conjugates (RDCs) Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 DIAGNOSTIC RADIONUCLIDE DRUG CONJUGATES (RDCS) INDUSTRY CHAIN ANALYSIS
4.1 Diagnostic Radionuclide Drug Conjugates (RDCs) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF DIAGNOSTIC RADIONUCLIDE DRUG CONJUGATES (RDCS) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Diagnostic Radionuclide Drug Conjugates (RDCs) Market
5.7 ESG Ratings of Leading Companies
6 DIAGNOSTIC RADIONUCLIDE DRUG CONJUGATES (RDCS) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Type (2020-2025)
6.3 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Type (2020-2025)
6.4 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Price by Type (2020-2025)
7 DIAGNOSTIC RADIONUCLIDE DRUG CONJUGATES (RDCS) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Sales by Application (2020-2025)
7.3 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size (M USD) by Application (2020-2025)
7.4 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Growth Rate by Application (2020-2025)
8 DIAGNOSTIC RADIONUCLIDE DRUG CONJUGATES (RDCS) MARKET SALES BY REGION
8.1 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Region
8.1.1 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Region
8.1.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Region
8.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region
8.2.1 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region
8.2.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region
8.3 North America
8.3.1 North America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Country
8.3.2 North America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Country
8.4.2 Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Region
8.5.2 Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Country
8.6.2 South America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Region
8.7.2 Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 DIAGNOSTIC RADIONUCLIDE DRUG CONJUGATES (RDCS) MARKET PRODUCTION BY REGION
9.1 Global Production of Diagnostic Radionuclide Drug Conjugates (RDCs) by Region(2020-2025)
9.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Revenue Market Share by Region (2020-2025)
9.3 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Diagnostic Radionuclide Drug Conjugates (RDCs) Production
9.4.1 North America Diagnostic Radionuclide Drug Conjugates (RDCs) Production Growth Rate (2020-2025)
9.4.2 North America Diagnostic Radionuclide Drug Conjugates (RDCs) Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Production
9.5.1 Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Production Growth Rate (2020-2025)
9.5.2 Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Diagnostic Radionuclide Drug Conjugates (RDCs) Production (2020-2025)
9.6.1 Japan Diagnostic Radionuclide Drug Conjugates (RDCs) Production Growth Rate (2020-2025)
9.6.2 Japan Diagnostic Radionuclide Drug Conjugates (RDCs) Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Diagnostic Radionuclide Drug Conjugates (RDCs) Production (2020-2025)
9.7.1 China Diagnostic Radionuclide Drug Conjugates (RDCs) Production Growth Rate (2020-2025)
9.7.2 China Diagnostic Radionuclide Drug Conjugates (RDCs) Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Novartis
10.1.1 Novartis Basic Information
10.1.2 Novartis Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.1.3 Novartis Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.1.4 Novartis Business Overview
10.1.5 Novartis SWOT Analysis
10.1.6 Novartis Recent Developments
10.2 Bayer
10.2.1 Bayer Basic Information
10.2.2 Bayer Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.2.3 Bayer Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.2.4 Bayer Business Overview
10.2.5 Bayer SWOT Analysis
10.2.6 Bayer Recent Developments
10.3 AstraZeneca
10.3.1 AstraZeneca Basic Information
10.3.2 AstraZeneca Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.3.3 AstraZeneca Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.3.4 AstraZeneca Business Overview
10.3.5 AstraZeneca SWOT Analysis
10.3.6 AstraZeneca Recent Developments
10.4 Eli Lilly
10.4.1 Eli Lilly Basic Information
10.4.2 Eli Lilly Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.4.3 Eli Lilly Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.4.4 Eli Lilly Business Overview
10.4.5 Eli Lilly Recent Developments
10.5 BMS
10.5.1 BMS Basic Information
10.5.2 BMS Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.5.3 BMS Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.5.4 BMS Business Overview
10.5.5 BMS Recent Developments
10.6 Johnson and Johnson
10.6.1 Johnson and Johnson Basic Information
10.6.2 Johnson and Johnson Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.6.3 Johnson and Johnson Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.6.4 Johnson and Johnson Business Overview
10.6.5 Johnson and Johnson Recent Developments
10.7 Bivision
10.7.1 Bivision Basic Information
10.7.2 Bivision Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.7.3 Bivision Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.7.4 Bivision Business Overview
10.7.5 Bivision Recent Developments
10.8 Grand Pharmaceutical Group Limited
10.8.1 Grand Pharmaceutical Group Limited Basic Information
10.8.2 Grand Pharmaceutical Group Limited Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.8.3 Grand Pharmaceutical Group Limited Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.8.4 Grand Pharmaceutical Group Limited Business Overview
10.8.5 Grand Pharmaceutical Group Limited Recent Developments
10.9 China Isotope and Radiation Corporation
10.9.1 China Isotope and Radiation Corporation Basic Information
10.9.2 China Isotope and Radiation Corporation Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.9.3 China Isotope and Radiation Corporation Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.9.4 China Isotope and Radiation Corporation Business Overview
10.9.5 China Isotope and Radiation Corporation Recent Developments
10.10 Yantai Dongcheng Pharmaceutical Group Co., Ltd.
10.10.1 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Basic Information
10.10.2 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.10.3 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.10.4 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Business Overview
10.10.5 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Recent Developments
10.11 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
10.11.1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Basic Information
10.11.2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.11.3 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.11.4 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Business Overview
10.11.5 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments
10.12 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
10.12.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Basic Information
10.12.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.12.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.12.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Business Overview
10.12.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments
10.13 SmartNuclide
10.13.1 SmartNuclide Basic Information
10.13.2 SmartNuclide Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.13.3 SmartNuclide Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.13.4 SmartNuclide Business Overview
10.13.5 SmartNuclide Recent Developments
10.14 Full-Life Technologies
10.14.1 Full-Life Technologies Basic Information
10.14.2 Full-Life Technologies Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.14.3 Full-Life Technologies Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.14.4 Full-Life Technologies Business Overview
10.14.5 Full-Life Technologies Recent Developments
10.15 Qingdao Baheal Medical INC.
10.15.1 Qingdao Baheal Medical INC. Basic Information
10.15.2 Qingdao Baheal Medical INC. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.15.3 Qingdao Baheal Medical INC. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.15.4 Qingdao Baheal Medical INC. Business Overview
10.15.5 Qingdao Baheal Medical INC. Recent Developments
10.16 Yunnan Baiyao
10.16.1 Yunnan Baiyao Basic Information
10.16.2 Yunnan Baiyao Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.16.3 Yunnan Baiyao Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.16.4 Yunnan Baiyao Business Overview
10.16.5 Yunnan Baiyao Recent Developments
10.17 TOT Biopharm International Company Limited
10.17.1 TOT Biopharm International Company Limited Basic Information
10.17.2 TOT Biopharm International Company Limited Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.17.3 TOT Biopharm International Company Limited Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.17.4 TOT Biopharm International Company Limited Business Overview
10.17.5 TOT Biopharm International Company Limited Recent Developments
10.18 Nuoyu Pharmaceutical
10.18.1 Nuoyu Pharmaceutical Basic Information
10.18.2 Nuoyu Pharmaceutical Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.18.3 Nuoyu Pharmaceutical Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.18.4 Nuoyu Pharmaceutical Business Overview
10.18.5 Nuoyu Pharmaceutical Recent Developments
10.19 Foshan Ruidio Medical System Co., Ltd.
10.19.1 Foshan Ruidio Medical System Co., Ltd. Basic Information
10.19.2 Foshan Ruidio Medical System Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.19.3 Foshan Ruidio Medical System Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.19.4 Foshan Ruidio Medical System Co., Ltd. Business Overview
10.19.5 Foshan Ruidio Medical System Co., Ltd. Recent Developments
10.20 Chengdu Yunke Pharmaceutical Co., Ltd.
10.20.1 Chengdu Yunke Pharmaceutical Co., Ltd. Basic Information
10.20.2 Chengdu Yunke Pharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.20.3 Chengdu Yunke Pharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.20.4 Chengdu Yunke Pharmaceutical Co., Ltd. Business Overview
10.20.5 Chengdu Yunke Pharmaceutical Co., Ltd. Recent Developments
10.21 Shandong Andike Pharmaceutical Co., Ltd.
10.21.1 Shandong Andike Pharmaceutical Co., Ltd. Basic Information
10.21.2 Shandong Andike Pharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.21.3 Shandong Andike Pharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.21.4 Shandong Andike Pharmaceutical Co., Ltd. Business Overview
10.21.5 Shandong Andike Pharmaceutical Co., Ltd. Recent Developments
10.22 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.
10.22.1 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Basic Information
10.22.2 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.22.3 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.22.4 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Business Overview
10.22.5 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Recent Developments
10.23 Sinotau
10.23.1 Sinotau Basic Information
10.23.2 Sinotau Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.23.3 Sinotau Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.23.4 Sinotau Business Overview
10.23.5 Sinotau Recent Developments
11 DIAGNOSTIC RADIONUCLIDE DRUG CONJUGATES (RDCS) MARKET FORECAST BY REGION
11.1 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast
11.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Country
11.2.3 Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Region
11.2.4 South America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Diagnostic Radionuclide Drug Conjugates (RDCs) by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Diagnostic Radionuclide Drug Conjugates (RDCs) by Type (2026-2035)
12.1.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Diagnostic Radionuclide Drug Conjugates (RDCs) by Type (2026-2035)
12.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Forecast by Application (2026-2035)
12.2.1 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT) Forecast by Application
12.2.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Diagnostic Radionuclide Drug Conjugates (RDCs)
1.2 Key Market Segments
1.2.1 Diagnostic Radionuclide Drug Conjugates (RDCs) Segment by Type
1.2.2 Diagnostic Radionuclide Drug Conjugates (RDCs) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 DIAGNOSTIC RADIONUCLIDE DRUG CONJUGATES (RDCS) MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 DIAGNOSTIC RADIONUCLIDE DRUG CONJUGATES (RDCS) MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Product Life Cycle
3.3 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Manufacturers (2020-2025)
3.4 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Revenue Market Share by Manufacturers (2020-2025)
3.5 Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Diagnostic Radionuclide Drug Conjugates (RDCs) Market Competitive Situation and Trends
3.8.1 Diagnostic Radionuclide Drug Conjugates (RDCs) Market Concentration Rate
3.8.2 Global 5 and 10 Largest Diagnostic Radionuclide Drug Conjugates (RDCs) Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 DIAGNOSTIC RADIONUCLIDE DRUG CONJUGATES (RDCS) INDUSTRY CHAIN ANALYSIS
4.1 Diagnostic Radionuclide Drug Conjugates (RDCs) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF DIAGNOSTIC RADIONUCLIDE DRUG CONJUGATES (RDCS) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Diagnostic Radionuclide Drug Conjugates (RDCs) Market
5.7 ESG Ratings of Leading Companies
6 DIAGNOSTIC RADIONUCLIDE DRUG CONJUGATES (RDCS) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Type (2020-2025)
6.3 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Type (2020-2025)
6.4 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Price by Type (2020-2025)
7 DIAGNOSTIC RADIONUCLIDE DRUG CONJUGATES (RDCS) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Sales by Application (2020-2025)
7.3 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size (M USD) by Application (2020-2025)
7.4 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Growth Rate by Application (2020-2025)
8 DIAGNOSTIC RADIONUCLIDE DRUG CONJUGATES (RDCS) MARKET SALES BY REGION
8.1 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Region
8.1.1 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Region
8.1.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Region
8.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region
8.2.1 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region
8.2.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region
8.3 North America
8.3.1 North America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Country
8.3.2 North America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Country
8.4.2 Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Region
8.5.2 Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Country
8.6.2 South America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Region
8.7.2 Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 DIAGNOSTIC RADIONUCLIDE DRUG CONJUGATES (RDCS) MARKET PRODUCTION BY REGION
9.1 Global Production of Diagnostic Radionuclide Drug Conjugates (RDCs) by Region(2020-2025)
9.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Revenue Market Share by Region (2020-2025)
9.3 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Diagnostic Radionuclide Drug Conjugates (RDCs) Production
9.4.1 North America Diagnostic Radionuclide Drug Conjugates (RDCs) Production Growth Rate (2020-2025)
9.4.2 North America Diagnostic Radionuclide Drug Conjugates (RDCs) Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Production
9.5.1 Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Production Growth Rate (2020-2025)
9.5.2 Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Diagnostic Radionuclide Drug Conjugates (RDCs) Production (2020-2025)
9.6.1 Japan Diagnostic Radionuclide Drug Conjugates (RDCs) Production Growth Rate (2020-2025)
9.6.2 Japan Diagnostic Radionuclide Drug Conjugates (RDCs) Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Diagnostic Radionuclide Drug Conjugates (RDCs) Production (2020-2025)
9.7.1 China Diagnostic Radionuclide Drug Conjugates (RDCs) Production Growth Rate (2020-2025)
9.7.2 China Diagnostic Radionuclide Drug Conjugates (RDCs) Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Novartis
10.1.1 Novartis Basic Information
10.1.2 Novartis Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.1.3 Novartis Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.1.4 Novartis Business Overview
10.1.5 Novartis SWOT Analysis
10.1.6 Novartis Recent Developments
10.2 Bayer
10.2.1 Bayer Basic Information
10.2.2 Bayer Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.2.3 Bayer Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.2.4 Bayer Business Overview
10.2.5 Bayer SWOT Analysis
10.2.6 Bayer Recent Developments
10.3 AstraZeneca
10.3.1 AstraZeneca Basic Information
10.3.2 AstraZeneca Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.3.3 AstraZeneca Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.3.4 AstraZeneca Business Overview
10.3.5 AstraZeneca SWOT Analysis
10.3.6 AstraZeneca Recent Developments
10.4 Eli Lilly
10.4.1 Eli Lilly Basic Information
10.4.2 Eli Lilly Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.4.3 Eli Lilly Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.4.4 Eli Lilly Business Overview
10.4.5 Eli Lilly Recent Developments
10.5 BMS
10.5.1 BMS Basic Information
10.5.2 BMS Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.5.3 BMS Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.5.4 BMS Business Overview
10.5.5 BMS Recent Developments
10.6 Johnson and Johnson
10.6.1 Johnson and Johnson Basic Information
10.6.2 Johnson and Johnson Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.6.3 Johnson and Johnson Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.6.4 Johnson and Johnson Business Overview
10.6.5 Johnson and Johnson Recent Developments
10.7 Bivision
10.7.1 Bivision Basic Information
10.7.2 Bivision Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.7.3 Bivision Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.7.4 Bivision Business Overview
10.7.5 Bivision Recent Developments
10.8 Grand Pharmaceutical Group Limited
10.8.1 Grand Pharmaceutical Group Limited Basic Information
10.8.2 Grand Pharmaceutical Group Limited Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.8.3 Grand Pharmaceutical Group Limited Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.8.4 Grand Pharmaceutical Group Limited Business Overview
10.8.5 Grand Pharmaceutical Group Limited Recent Developments
10.9 China Isotope and Radiation Corporation
10.9.1 China Isotope and Radiation Corporation Basic Information
10.9.2 China Isotope and Radiation Corporation Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.9.3 China Isotope and Radiation Corporation Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.9.4 China Isotope and Radiation Corporation Business Overview
10.9.5 China Isotope and Radiation Corporation Recent Developments
10.10 Yantai Dongcheng Pharmaceutical Group Co., Ltd.
10.10.1 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Basic Information
10.10.2 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.10.3 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.10.4 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Business Overview
10.10.5 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Recent Developments
10.11 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
10.11.1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Basic Information
10.11.2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.11.3 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.11.4 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Business Overview
10.11.5 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments
10.12 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
10.12.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Basic Information
10.12.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.12.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.12.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Business Overview
10.12.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments
10.13 SmartNuclide
10.13.1 SmartNuclide Basic Information
10.13.2 SmartNuclide Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.13.3 SmartNuclide Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.13.4 SmartNuclide Business Overview
10.13.5 SmartNuclide Recent Developments
10.14 Full-Life Technologies
10.14.1 Full-Life Technologies Basic Information
10.14.2 Full-Life Technologies Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.14.3 Full-Life Technologies Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.14.4 Full-Life Technologies Business Overview
10.14.5 Full-Life Technologies Recent Developments
10.15 Qingdao Baheal Medical INC.
10.15.1 Qingdao Baheal Medical INC. Basic Information
10.15.2 Qingdao Baheal Medical INC. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.15.3 Qingdao Baheal Medical INC. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.15.4 Qingdao Baheal Medical INC. Business Overview
10.15.5 Qingdao Baheal Medical INC. Recent Developments
10.16 Yunnan Baiyao
10.16.1 Yunnan Baiyao Basic Information
10.16.2 Yunnan Baiyao Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.16.3 Yunnan Baiyao Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.16.4 Yunnan Baiyao Business Overview
10.16.5 Yunnan Baiyao Recent Developments
10.17 TOT Biopharm International Company Limited
10.17.1 TOT Biopharm International Company Limited Basic Information
10.17.2 TOT Biopharm International Company Limited Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.17.3 TOT Biopharm International Company Limited Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.17.4 TOT Biopharm International Company Limited Business Overview
10.17.5 TOT Biopharm International Company Limited Recent Developments
10.18 Nuoyu Pharmaceutical
10.18.1 Nuoyu Pharmaceutical Basic Information
10.18.2 Nuoyu Pharmaceutical Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.18.3 Nuoyu Pharmaceutical Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.18.4 Nuoyu Pharmaceutical Business Overview
10.18.5 Nuoyu Pharmaceutical Recent Developments
10.19 Foshan Ruidio Medical System Co., Ltd.
10.19.1 Foshan Ruidio Medical System Co., Ltd. Basic Information
10.19.2 Foshan Ruidio Medical System Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.19.3 Foshan Ruidio Medical System Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.19.4 Foshan Ruidio Medical System Co., Ltd. Business Overview
10.19.5 Foshan Ruidio Medical System Co., Ltd. Recent Developments
10.20 Chengdu Yunke Pharmaceutical Co., Ltd.
10.20.1 Chengdu Yunke Pharmaceutical Co., Ltd. Basic Information
10.20.2 Chengdu Yunke Pharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.20.3 Chengdu Yunke Pharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.20.4 Chengdu Yunke Pharmaceutical Co., Ltd. Business Overview
10.20.5 Chengdu Yunke Pharmaceutical Co., Ltd. Recent Developments
10.21 Shandong Andike Pharmaceutical Co., Ltd.
10.21.1 Shandong Andike Pharmaceutical Co., Ltd. Basic Information
10.21.2 Shandong Andike Pharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.21.3 Shandong Andike Pharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.21.4 Shandong Andike Pharmaceutical Co., Ltd. Business Overview
10.21.5 Shandong Andike Pharmaceutical Co., Ltd. Recent Developments
10.22 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.
10.22.1 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Basic Information
10.22.2 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.22.3 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.22.4 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Business Overview
10.22.5 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Recent Developments
10.23 Sinotau
10.23.1 Sinotau Basic Information
10.23.2 Sinotau Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
10.23.3 Sinotau Diagnostic Radionuclide Drug Conjugates (RDCs) Product Market Performance
10.23.4 Sinotau Business Overview
10.23.5 Sinotau Recent Developments
11 DIAGNOSTIC RADIONUCLIDE DRUG CONJUGATES (RDCS) MARKET FORECAST BY REGION
11.1 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast
11.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Country
11.2.3 Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Region
11.2.4 South America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Diagnostic Radionuclide Drug Conjugates (RDCs) by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Diagnostic Radionuclide Drug Conjugates (RDCs) by Type (2026-2035)
12.1.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Diagnostic Radionuclide Drug Conjugates (RDCs) by Type (2026-2035)
12.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Forecast by Application (2026-2035)
12.2.1 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT) Forecast by Application
12.2.2 Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Type (M USD)
Table 4. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Application
Table 5. Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Comparison by Region (M USD)
Table 6. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diagnostic Radionuclide Drug Conjugates (RDCs) as of 2025)
Table 11. Global Market Diagnostic Radionuclide Drug Conjugates (RDCs) Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Diagnostic Radionuclide Drug Conjugates (RDCs) Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Type (K MT)
Table 27. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Type (M USD)
Table 28. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT) by Type (2020-2025)
Table 29. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Type (2020-2025)
Table 30. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size (M USD) by Type (2020-2025)
Table 31. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share by Type (2020-2025)
Table 32. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Price (USD/KG) by Type (2020-2025)
Table 33. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT) by Application
Table 34. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Application
Table 35. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Application (2020-2025) & (K MT)
Table 36. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Application (2020-2025)
Table 37. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Application (2020-2025) & (M USD)
Table 38. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share by Application (2020-2025)
Table 39. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Growth Rate by Application (2020-2025)
Table 40. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Region (2020-2025) & (K MT)
Table 41. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Region (2020-2025)
Table 42. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region (2020-2025) & (M USD)
Table 43. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region (2020-2025)
Table 44. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Country (2020-2025) & (K MT)
Table 45. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Country (2020-2025) & (K MT)
Table 47. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region (2020-2025) & (M USD)
Table 50. South America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Country (2020-2025) & (K MT)
Table 51. South America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region (2020-2025) & (M USD)
Table 54. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT) by Region(2020-2025)
Table 55. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Revenue Market Share by Region (2020-2025)
Table 57. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Novartis Basic Information
Table 63. Novartis Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 64. Novartis Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Novartis Business Overview
Table 66. Novartis SWOT Analysis
Table 67. Novartis Recent Developments
Table 68. Bayer Basic Information
Table 69. Bayer Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 70. Bayer Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Bayer Business Overview
Table 72. Bayer SWOT Analysis
Table 73. Bayer Recent Developments
Table 74. AstraZeneca Basic Information
Table 75. AstraZeneca Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 76. AstraZeneca Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. AstraZeneca Business Overview
Table 78. AstraZeneca SWOT Analysis
Table 79. AstraZeneca Recent Developments
Table 80. Eli Lilly Basic Information
Table 81. Eli Lilly Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 82. Eli Lilly Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Eli Lilly Business Overview
Table 84. Eli Lilly Recent Developments
Table 85. BMS Basic Information
Table 86. BMS Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 87. BMS Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. BMS Business Overview
Table 89. BMS Recent Developments
Table 90. Johnson and Johnson Basic Information
Table 91. Johnson and Johnson Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 92. Johnson and Johnson Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Johnson and Johnson Business Overview
Table 94. Johnson and Johnson Recent Developments
Table 95. Bivision Basic Information
Table 96. Bivision Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 97. Bivision Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Bivision Business Overview
Table 99. Bivision Recent Developments
Table 100. Grand Pharmaceutical Group Limited Basic Information
Table 101. Grand Pharmaceutical Group Limited Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 102. Grand Pharmaceutical Group Limited Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. Grand Pharmaceutical Group Limited Business Overview
Table 104. Grand Pharmaceutical Group Limited Recent Developments
Table 105. China Isotope and Radiation Corporation Basic Information
Table 106. China Isotope and Radiation Corporation Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 107. China Isotope and Radiation Corporation Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. China Isotope and Radiation Corporation Business Overview
Table 109. China Isotope and Radiation Corporation Recent Developments
Table 110. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Basic Information
Table 111. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 112. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Business Overview
Table 114. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Recent Developments
Table 115. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Basic Information
Table 116. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 117. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Business Overview
Table 119. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments
Table 120. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Basic Information
Table 121. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 122. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 123. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Business Overview
Table 124. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments
Table 125. SmartNuclide Basic Information
Table 126. SmartNuclide Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 127. SmartNuclide Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 128. SmartNuclide Business Overview
Table 129. SmartNuclide Recent Developments
Table 130. Full-Life Technologies Basic Information
Table 131. Full-Life Technologies Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 132. Full-Life Technologies Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 133. Full-Life Technologies Business Overview
Table 134. Full-Life Technologies Recent Developments
Table 135. Qingdao Baheal Medical INC. Basic Information
Table 136. Qingdao Baheal Medical INC. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 137. Qingdao Baheal Medical INC. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 138. Qingdao Baheal Medical INC. Business Overview
Table 139. Qingdao Baheal Medical INC. Recent Developments
Table 140. Yunnan Baiyao Basic Information
Table 141. Yunnan Baiyao Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 142. Yunnan Baiyao Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 143. Yunnan Baiyao Business Overview
Table 144. Yunnan Baiyao Recent Developments
Table 145. TOT Biopharm International Company Limited Basic Information
Table 146. TOT Biopharm International Company Limited Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 147. TOT Biopharm International Company Limited Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 148. TOT Biopharm International Company Limited Business Overview
Table 149. TOT Biopharm International Company Limited Recent Developments
Table 150. Nuoyu Pharmaceutical Basic Information
Table 151. Nuoyu Pharmaceutical Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 152. Nuoyu Pharmaceutical Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 153. Nuoyu Pharmaceutical Business Overview
Table 154. Nuoyu Pharmaceutical Recent Developments
Table 155. Foshan Ruidio Medical System Co., Ltd. Basic Information
Table 156. Foshan Ruidio Medical System Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 157. Foshan Ruidio Medical System Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 158. Foshan Ruidio Medical System Co., Ltd. Business Overview
Table 159. Foshan Ruidio Medical System Co., Ltd. Recent Developments
Table 160. Chengdu Yunke Pharmaceutical Co., Ltd. Basic Information
Table 161. Chengdu Yunke Pharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 162. Chengdu Yunke Pharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 163. Chengdu Yunke Pharmaceutical Co., Ltd. Business Overview
Table 164. Chengdu Yunke Pharmaceutical Co., Ltd. Recent Developments
Table 165. Shandong Andike Pharmaceutical Co., Ltd. Basic Information
Table 166. Shandong Andike Pharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 167. Shandong Andike Pharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 168. Shandong Andike Pharmaceutical Co., Ltd. Business Overview
Table 169. Shandong Andike Pharmaceutical Co., Ltd. Recent Developments
Table 170. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Basic Information
Table 171. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 172. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 173. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Business Overview
Table 174. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Recent Developments
Table 175. Sinotau Basic Information
Table 176. Sinotau Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 177. Sinotau Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 178. Sinotau Business Overview
Table 179. Sinotau Recent Developments
Table 180. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Forecast by Region (2026-2035) & (K MT)
Table 181. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Region (2026-2035) & (M USD)
Table 182. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Forecast by Country (2026-2035) & (K MT)
Table 183. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Country (2026-2035) & (M USD)
Table 184. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Forecast by Country (2026-2035) & (K MT)
Table 185. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Country (2026-2035) & (M USD)
Table 186. Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Forecast by Region (2026-2035) & (K MT)
Table 187. Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Region (2026-2035) & (M USD)
Table 188. South America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Forecast by Country (2026-2035) & (K MT)
Table 189. South America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Country (2026-2035) & (M USD)
Table 190. Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Forecast by Country (2026-2035) & (Units)
Table 191. Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Country (2026-2035) & (M USD)
Table 192. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Forecast by Type (2026-2035) & (K MT)
Table 193. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Type (2026-2035) & (M USD)
Table 194. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Price Forecast by Type (2026-2035) & (USD/KG)
Table 195. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT) Forecast by Application (2026-2035)
Table 196. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Type (M USD)
Table 4. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Application
Table 5. Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Comparison by Region (M USD)
Table 6. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diagnostic Radionuclide Drug Conjugates (RDCs) as of 2025)
Table 11. Global Market Diagnostic Radionuclide Drug Conjugates (RDCs) Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Diagnostic Radionuclide Drug Conjugates (RDCs) Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Type (K MT)
Table 27. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Type (M USD)
Table 28. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT) by Type (2020-2025)
Table 29. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Type (2020-2025)
Table 30. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size (M USD) by Type (2020-2025)
Table 31. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share by Type (2020-2025)
Table 32. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Price (USD/KG) by Type (2020-2025)
Table 33. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT) by Application
Table 34. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Application
Table 35. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Application (2020-2025) & (K MT)
Table 36. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Application (2020-2025)
Table 37. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Application (2020-2025) & (M USD)
Table 38. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share by Application (2020-2025)
Table 39. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Growth Rate by Application (2020-2025)
Table 40. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Region (2020-2025) & (K MT)
Table 41. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Region (2020-2025)
Table 42. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region (2020-2025) & (M USD)
Table 43. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region (2020-2025)
Table 44. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Country (2020-2025) & (K MT)
Table 45. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Country (2020-2025) & (K MT)
Table 47. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region (2020-2025) & (M USD)
Table 50. South America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Country (2020-2025) & (K MT)
Table 51. South America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region (2020-2025) & (M USD)
Table 54. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT) by Region(2020-2025)
Table 55. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Revenue Market Share by Region (2020-2025)
Table 57. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Novartis Basic Information
Table 63. Novartis Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 64. Novartis Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Novartis Business Overview
Table 66. Novartis SWOT Analysis
Table 67. Novartis Recent Developments
Table 68. Bayer Basic Information
Table 69. Bayer Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 70. Bayer Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Bayer Business Overview
Table 72. Bayer SWOT Analysis
Table 73. Bayer Recent Developments
Table 74. AstraZeneca Basic Information
Table 75. AstraZeneca Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 76. AstraZeneca Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. AstraZeneca Business Overview
Table 78. AstraZeneca SWOT Analysis
Table 79. AstraZeneca Recent Developments
Table 80. Eli Lilly Basic Information
Table 81. Eli Lilly Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 82. Eli Lilly Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Eli Lilly Business Overview
Table 84. Eli Lilly Recent Developments
Table 85. BMS Basic Information
Table 86. BMS Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 87. BMS Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. BMS Business Overview
Table 89. BMS Recent Developments
Table 90. Johnson and Johnson Basic Information
Table 91. Johnson and Johnson Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 92. Johnson and Johnson Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Johnson and Johnson Business Overview
Table 94. Johnson and Johnson Recent Developments
Table 95. Bivision Basic Information
Table 96. Bivision Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 97. Bivision Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Bivision Business Overview
Table 99. Bivision Recent Developments
Table 100. Grand Pharmaceutical Group Limited Basic Information
Table 101. Grand Pharmaceutical Group Limited Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 102. Grand Pharmaceutical Group Limited Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. Grand Pharmaceutical Group Limited Business Overview
Table 104. Grand Pharmaceutical Group Limited Recent Developments
Table 105. China Isotope and Radiation Corporation Basic Information
Table 106. China Isotope and Radiation Corporation Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 107. China Isotope and Radiation Corporation Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. China Isotope and Radiation Corporation Business Overview
Table 109. China Isotope and Radiation Corporation Recent Developments
Table 110. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Basic Information
Table 111. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 112. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Business Overview
Table 114. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Recent Developments
Table 115. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Basic Information
Table 116. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 117. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Business Overview
Table 119. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments
Table 120. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Basic Information
Table 121. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 122. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 123. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Business Overview
Table 124. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments
Table 125. SmartNuclide Basic Information
Table 126. SmartNuclide Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 127. SmartNuclide Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 128. SmartNuclide Business Overview
Table 129. SmartNuclide Recent Developments
Table 130. Full-Life Technologies Basic Information
Table 131. Full-Life Technologies Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 132. Full-Life Technologies Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 133. Full-Life Technologies Business Overview
Table 134. Full-Life Technologies Recent Developments
Table 135. Qingdao Baheal Medical INC. Basic Information
Table 136. Qingdao Baheal Medical INC. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 137. Qingdao Baheal Medical INC. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 138. Qingdao Baheal Medical INC. Business Overview
Table 139. Qingdao Baheal Medical INC. Recent Developments
Table 140. Yunnan Baiyao Basic Information
Table 141. Yunnan Baiyao Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 142. Yunnan Baiyao Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 143. Yunnan Baiyao Business Overview
Table 144. Yunnan Baiyao Recent Developments
Table 145. TOT Biopharm International Company Limited Basic Information
Table 146. TOT Biopharm International Company Limited Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 147. TOT Biopharm International Company Limited Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 148. TOT Biopharm International Company Limited Business Overview
Table 149. TOT Biopharm International Company Limited Recent Developments
Table 150. Nuoyu Pharmaceutical Basic Information
Table 151. Nuoyu Pharmaceutical Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 152. Nuoyu Pharmaceutical Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 153. Nuoyu Pharmaceutical Business Overview
Table 154. Nuoyu Pharmaceutical Recent Developments
Table 155. Foshan Ruidio Medical System Co., Ltd. Basic Information
Table 156. Foshan Ruidio Medical System Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 157. Foshan Ruidio Medical System Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 158. Foshan Ruidio Medical System Co., Ltd. Business Overview
Table 159. Foshan Ruidio Medical System Co., Ltd. Recent Developments
Table 160. Chengdu Yunke Pharmaceutical Co., Ltd. Basic Information
Table 161. Chengdu Yunke Pharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 162. Chengdu Yunke Pharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 163. Chengdu Yunke Pharmaceutical Co., Ltd. Business Overview
Table 164. Chengdu Yunke Pharmaceutical Co., Ltd. Recent Developments
Table 165. Shandong Andike Pharmaceutical Co., Ltd. Basic Information
Table 166. Shandong Andike Pharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 167. Shandong Andike Pharmaceutical Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 168. Shandong Andike Pharmaceutical Co., Ltd. Business Overview
Table 169. Shandong Andike Pharmaceutical Co., Ltd. Recent Developments
Table 170. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Basic Information
Table 171. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 172. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 173. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Business Overview
Table 174. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Recent Developments
Table 175. Sinotau Basic Information
Table 176. Sinotau Diagnostic Radionuclide Drug Conjugates (RDCs) Product Overview
Table 177. Sinotau Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 178. Sinotau Business Overview
Table 179. Sinotau Recent Developments
Table 180. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Forecast by Region (2026-2035) & (K MT)
Table 181. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Region (2026-2035) & (M USD)
Table 182. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Forecast by Country (2026-2035) & (K MT)
Table 183. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Country (2026-2035) & (M USD)
Table 184. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Forecast by Country (2026-2035) & (K MT)
Table 185. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Country (2026-2035) & (M USD)
Table 186. Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Forecast by Region (2026-2035) & (K MT)
Table 187. Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Region (2026-2035) & (M USD)
Table 188. South America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Forecast by Country (2026-2035) & (K MT)
Table 189. South America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Country (2026-2035) & (M USD)
Table 190. Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Forecast by Country (2026-2035) & (Units)
Table 191. Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Country (2026-2035) & (M USD)
Table 192. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Forecast by Type (2026-2035) & (K MT)
Table 193. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Type (2026-2035) & (M USD)
Table 194. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Price Forecast by Type (2026-2035) & (USD/KG)
Table 195. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT) Forecast by Application (2026-2035)
Table 196. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Diagnostic Radionuclide Drug Conjugates (RDCs)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size (M USD), 2025-2035
Figure 5. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size (M USD) (2020-2035)
Figure 6. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Product Life Cycle
Figure 13. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Share by Manufacturers in 2025
Figure 14. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Revenue Share by Manufacturers in 2025
Figure 15. Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Diagnostic Radionuclide Drug Conjugates (RDCs) Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Diagnostic Radionuclide Drug Conjugates (RDCs) Revenue in 2025
Figure 18. Industry Chain Map of Diagnostic Radionuclide Drug Conjugates (RDCs)
Figure 19. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market PEST Analysis
Figure 20. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share by Type
Figure 27. Sales Market Share of Diagnostic Radionuclide Drug Conjugates (RDCs) by Type (2020-2025)
Figure 28. Sales Market Share of Diagnostic Radionuclide Drug Conjugates (RDCs) by Type in 2025
Figure 29. Market Share of Diagnostic Radionuclide Drug Conjugates (RDCs) by Type (2020-2025)
Figure 30. Market Share of Diagnostic Radionuclide Drug Conjugates (RDCs) by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share by Application
Figure 33. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Application (2020-2025)
Figure 34. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Application in 2025
Figure 35. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share by Application (2020-2025)
Figure 36. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share by Application in 2025
Figure 37. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Growth Rate by Application (2020-2025)
Figure 38. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Region (2020-2025)
Figure 39. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region (2020-2025)
Figure 40. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Country in 2024
Figure 43. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country in 2024
Figure 45. U.S. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Country in 2024
Figure 53. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country in 2024
Figure 55. Germany Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Region in 2024
Figure 67. Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region in 2024
Figure 68. China Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (K MT)
Figure 79. South America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Country in 2024
Figure 80. South America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (M USD)
Figure 81. South America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country in 2024
Figure 82. Brazil Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region in 2024
Figure 92. Saudi Arabia Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Production Market Share by Region (2020-2025)
Figure 103. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT) Growth Rate (2020-2025)
Figure 106. China Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share Forecast by Type (2026-2035)
Figure 111. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Forecast by Application (2026-2035)
Figure 112. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share Forecast by Application (2026-2035)
Figure 1. Product Picture of Diagnostic Radionuclide Drug Conjugates (RDCs)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size (M USD), 2025-2035
Figure 5. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size (M USD) (2020-2035)
Figure 6. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Product Life Cycle
Figure 13. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Share by Manufacturers in 2025
Figure 14. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Revenue Share by Manufacturers in 2025
Figure 15. Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Diagnostic Radionuclide Drug Conjugates (RDCs) Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Diagnostic Radionuclide Drug Conjugates (RDCs) Revenue in 2025
Figure 18. Industry Chain Map of Diagnostic Radionuclide Drug Conjugates (RDCs)
Figure 19. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market PEST Analysis
Figure 20. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share by Type
Figure 27. Sales Market Share of Diagnostic Radionuclide Drug Conjugates (RDCs) by Type (2020-2025)
Figure 28. Sales Market Share of Diagnostic Radionuclide Drug Conjugates (RDCs) by Type in 2025
Figure 29. Market Share of Diagnostic Radionuclide Drug Conjugates (RDCs) by Type (2020-2025)
Figure 30. Market Share of Diagnostic Radionuclide Drug Conjugates (RDCs) by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share by Application
Figure 33. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Application (2020-2025)
Figure 34. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Application in 2025
Figure 35. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share by Application (2020-2025)
Figure 36. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share by Application in 2025
Figure 37. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Growth Rate by Application (2020-2025)
Figure 38. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Region (2020-2025)
Figure 39. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region (2020-2025)
Figure 40. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Country in 2024
Figure 43. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country in 2024
Figure 45. U.S. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Diagnostic Radionuclide Drug Conjugates (RDCs) Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Country in 2024
Figure 53. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country in 2024
Figure 55. Germany Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Region in 2024
Figure 67. Asia Pacific Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region in 2024
Figure 68. China Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (K MT)
Figure 79. South America Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Country in 2024
Figure 80. South America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (M USD)
Figure 81. South America Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Country in 2024
Figure 82. Brazil Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size by Region in 2024
Figure 92. Saudi Arabia Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Production Market Share by Region (2020-2025)
Figure 103. North America Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT) Growth Rate (2020-2025)
Figure 106. China Diagnostic Radionuclide Drug Conjugates (RDCs) Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share Forecast by Type (2026-2035)
Figure 111. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Sales Forecast by Application (2026-2035)
Figure 112. Global Diagnostic Radionuclide Drug Conjugates (RDCs) Market Share Forecast by Application (2026-2035)
